Almac devises test to detect likelihood of colon cancer recurring

November 8, 2011 in Cancer
Almac devises test to detect likelihood of colon cancer recurring

Enlarge

Professor Paul Harkin, President and Managing Director of Almac’s Diagnostic business unit which has devised a new test to detect likelihood of colon cancer recurring. Credit: Almac

The findings of Almac scientists' research have been published in the online version of the Journal of Clinical Oncology (JCO) ahead of the print edition of the journal. The JCO is the peer-reviewed publication of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.

Colon cancer is the third most common cancer in the US. Over 100,000 patients are diagnosed each year and around one quarter of these patients are diagnosed with stage 2 of the disease.

Stage 2 has a relatively good with around 80% of patients cured by surgery but the disease will recur in the remaining 20% within five years.

Although the 20% of patients in which the cancer recurs may benefit from chemotherapy there is currently no test which doctors can use to help identify them.

The JCO report gives detail on the development and validation of a prognostic test designed by Almac, ColDX, specifically developed to identify high risk patients who may benefit from additional therapy.

Professor Paul Harkin, President and Managing Director of Almac's Diagnostic business and Professor of Molecular Oncology at Queen's University Belfast said:

"We have used complex technologies designed in Craigavon, , to examine tumour samples from around the world to identify a which tell us the likelihood of stage 2 colon cancer recurring. This technology will make it much more straightforward for doctors to identify high who may benefit from .

"Our highly novel test represents a significant breakthrough in how colon cancer can be managed. We believe it has the potential to change clinical practice and save the lives of some . "Almac is committed to research which improves the health of people around the world and this is just one example of how we are working to achieve that."

Almac scientists including, Professor Richard Kennedy, Dr Max Bylesjo, Dr Peter Kerr, Dr Timothy Davison and Dr Vitali Proutski were involved in the research.

The test was developed using Almac's proprietary discovery technology and using clinical patient samples from around 14 clinical sites across the world including Queen's University Belfast.

Professor Patrick Johnston, Dean, School of Medicine, Dentistry and Biomedical Sciences at Queen's, said:

"We are pleased to have been able to play a role in helping Almac to develop this groundbreaking technology which we hope could save many lives in the future. Both Queen's and Almac are working tirelessly in advancing cancer research and treatments."

Following further external validation and commercialisation the test could be available to UK patients within a couple of years and potentially even sooner in the US.

More information: The full title of the article published in the Journal of Clinical Oncology is entitled: "Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue". http://jco.ascopub … 498.full.pdf

Provided by JPR

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts
  • Potential Breakthrough in Seizure Control
    created8 hours ago
  • Popping/Cracked sternum.
    created13 hours ago
  • Which Mental Illness Encompasses This Problem?
    created13 hours ago
  • A question about drug tolerance
    createdMay 23, 2012
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

Cancer created 21 hours ago | popularity not rated yet | comments 0 | with audio podcast

Pancreatectomy OK without downstaging from therapy

(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...

Cancer created 22 hours ago | popularity not rated yet | comments 0

Common therapies for basal cell carcinoma offer similar survival

(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published ...

Cancer created 23 hours ago | popularity not rated yet | comments 0

Cancer may require simpler genetic mutations than previously thought

Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...

Cancer created May 25, 2012 | popularity not rated yet | comments 0 | with audio podcast

New prostate cancer screening guidelines face a tough sell, study suggests

(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter ...

Cancer created May 25, 2012 | popularity not rated yet | comments 1


Travel to high altitudes tied to Crohn's, colitis flare-ups

(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...

Family history of Alzheimer's affects functional connectivity

(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...

Transvaginal mesh op restores pelvic organ prolapse at price

(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...

Tongue analysis software uses ancient Chinese medicine to warn of disease

For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...

Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare

A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...

New device allows pacemaker patients to safely undergo MRIs

For many, it's a medical conundrum: The very pacemaker keeping their heart in rhythm prevents them from undergoing an MRI to diagnose other ailments, because interaction between the two devices could prove deadly.